Abstract:BACKGROUND:Previous studies have shown that RNA Polymerase III Subunit G (POLR3G) has oncogenic effects in cultured cells and mice. However, the role of POLR3G in transitional cell carcinoma (TCC) has not been reported. This study explores the potential of POLR3G as a novel molecular marker for TCC.METHODS:The RNA sequencing data and clinical information of patients with TCC were downloaded from The Cancer Genome Atlas official website. Transcriptome analysis was performed as implemented in the edgeR package to explore whether POLR3G was up-regulated in TCC tissues compared to normal bladder tissues. The expression of POLR3G in bladder cancer cell line T24 and human uroepithelial cell line SV-HUC-1 were detected via quantitative real time polymerase chain reaction (qRT-PCR). Correlations between POLR3G expression and clinicopathological characteristics were analyzed using Mann-Whitney U test or Kruskal-Wallis H test. Clinicopathological characteristics associated with overall survival were explored using the Kaplan-Meier method and Cox regression analyses. Gene set enrichment analysis (GSEA) was performed to explore the associated gene sets enriched in different POLR3G expression phenotypes and the online tool Tumor IMmune Estimation Resource (TIMER) was used to explore the correlation between POLR3G expression and tumor immune infiltration in TCC.RESULTS:Transcriptome analysis showed that POLR3G was significantly up-regulated in TCC tissues compared to normal bladder tissues. Furthermore, qRT-PCR revealed high expression of POLR3G in T24 cells compared to SV-HUC-1 cells. Overall, POLR3G expression was associated with race, tumor status, tumor subtype, T classification, and pathological stage. Kaplan-Meier survival analysis revealed that higher POLR3G expression was associated with lower overall survival. The univariate Cox regression model revealed that age at diagnosis, pathological stage, and POLR3G expression were associated with prognosis of TCC patients. Further multivariate analyses identified these three clinicopathological characteristics as independent prognostic factors for overall survival. GSEA analysis showed that several gene sets associated with tumor development and metastasis, including TGF-β signaling, PI3K-AKT-mTOR signaling, and IL6-JAK-STAT3 signaling, were significantly enriched in POLR3G high expression phenotype. Immune infiltration analysis revealed that the expression of POLR3G was significantly correlated with infiltrating levels of immune cells, including CD8+ T cells, neutrophils, and dendritic cells; and the expression of POLR3G was also significantly correlated with the expression of immune checkpoint molecules, such as PD1, PD-L1, PD-L2, CTLA4, LAG3, HAVCR2, and TIGIT.CONCLUSIONS:POLR3G was up-regulated in TCC and high POLR3G expression correlated with poor prognosis. POLR3G can potentially be used as a prognostic marker for TCC and might be of great value in predicting the response to immunotherapy.

FOXO3A Expression in Upper Tract Urothelial Carcinoma

Absence of GATA3/FOXA1 co-expression predicts poor prognosis in upper tract urothelial carcinoma

Increased Expression of SOX2 Predicts A Poor Prognosis and Promotes Malignant Phenotypes in Upper Tract Urothelial Carcinoma

Prognostic value of HER2 expression levels for upper tract urothelial carcinoma.

Foxo3a Expression Is A Prognostic Marker In Breast Cancer

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study

Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma.

The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma

Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma

The Expression and Clinical Significance of PD-L1 in Patients with Upper Tract Urothelial Carcinoma.

Expression of GFRα3 Correlates with Tumor Progression and Promotes Cell Metastasis in Urothelial Carcinoma

Expression levels of transcription factors c-Fos and c-Jun and transmembrane protein HAb18G/CD147 in urothelial carcinoma of the bladder

FOXO3a deregulation in uterine smooth muscle tumors

Prognostic Significance of ROR2 Expression in Patients with Urothelial Carcinoma

Prognostic Value of UTX Expression in Patients with Clear Cell Renal Cell Carcinoma

Prognostic Significance of PD-L1 Expression on Tumor Cells and Tumor-Infiltrating Mononuclear Cells in Upper Tract Urothelial Carcinoma

High Expression Of Fut3 Is Linked To Poor Prognosis In Clear Cell Renal Cell Carcinoma

FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer

Expression Status of GATA3 and Mismatch Repair Proteins in Upper Tract Urothelial Carcinoma

Increased Expression of POLR3G Predicts Poor Prognosis in Transitional Cell Carcinoma.

Abnormal TACC3 Expression is an Independent Prognostic Biomarker in Lung Carcinoma